gastro-2017-keynote

3 / 5

Volume 7, Issue 3 (Suppl) J Gastrointest Dig Syst, an open access journal
ISSN: 2161-069X Gastro 2017
June 12-13, 2017
Page 25
Notes:
conferenceseries.com
June 12-13, 2017 Rome, Italy
11th Global
GastroenterologistsMeeting
Larry I Good, J Gastrointest Dig Syst 2017, 7:3(Suppl)
DOI: 10.4172/2161-069X-C1-048
Serum derived bovine immunoglobulin in the treatment of gastrointestinal disease
Serum derived bovine immunoglobulin was introduced as a medical food in the U.S. in 2013. Since then it has been studied
in over 800 patients with a variety of gastrointestinal illnesses including diarrhea predominant irritable bowel syndrome
(IBS-D), ulcerative colitis, Crohn’s disease, pouchitis, C. difficile colitis and chronic mesenteric ischemia. Its effectiveness
in these diverse disease entities is related to the ability of SBI to bind intraluminal pro-inflammatory mediators including
enterotoxins, pro-inflammatory cytokines and bacterial degradation products, thereby, preventing the loss of intercellular
tight junction proteins. By maintaining tight junction, integrity, dendritic antigenic stimulation in the mucosa is reduced,
resulting in inhibition of the inflammatory cascade. This presentation will review the US FDA category of medical foods,
the proposed mechanism of action SBI and published clinical data.
Biography
Larry I Good has been a practicing Gastroenterologist since 1978. He completed his Graduation at Colgate University in 1969; MD at Medical University of South Carolina
in Charleston, SC in 1973 and; Medical Residency from 1973-76. He was Chief Medical Resident in 1976. He completed his fellowship trained in Gastroenterology from
1976-78. He served as the Director of Liver Diseases at Nassau County Medical Center and was for many years Chief in Division of Gastroenterology, Department of
Medicine at South Nassau Communities Hospital. He is an Assistant Clinical Professor of Medicine at SUNY Stony Brook. He has given hundreds of lectures in his field
and has authored numerous papers and abstracts. Recently, he presented the ACG Theater lecture at American College of Gastroenterology annual meeting in Chicago,
Illinois in October, 2014. He was Chief Medical Officer at Ritter Pharmaceuticals in Los Angeles, California, where he expanded his research interest in the Intestinal Mi-
crobiome. His current clinical research activities involve the microbiome, inflammatory bowel disease, irritable bowel syndrome and the application of orally administered
gamma globulin to patients with acute and chronic gastro-intestinal disorders.
Larry I Good
1Good Pharmaceutical Development Company, USA
2South Nassau Communities Hospital, USA